Pharmacological subgroup
V03A – ALLE ÜBRIGEN THERAPEUTISCHEN MITTEL
11Decisions
14Patient groups
Added benefit by patient group
- Non-quantifiable2
- Not proven11
- Lesser benefit1
Subgroups
- V03AB Antidote 2 decisions
- V03AE Mittel zur Behandlung der Hyperkaliämie und Hyperphosphatämie 5 decisions
- V03AF Entgiftungsmittel für die Behandlung mit Zytostatika 1 decision
- V03AX Andere therapeutische Mittel 3 decisions
Decisions, newest first
- 2026-01-22OndexxyaAndexanet alfaNot proven: 1 of 2 patient groupsLesser benefit: 1 of 2 patient groups
- 2025-07-17PedmarqsiNatriumthiosulfatNon-quantifiable: 1 of 2 patient groupsNot proven: 1 of 2 patient groups
- 2024-08-01VeltassaPatiromerNot proven
- 2023-04-06KapruviaDifelikefalinNot proven
- 2022-10-06VoraxazeGlucarpidaseNon-quantifiable
- 2021-09-16LokelmaNatrium-ZirconiumcyclosilicatNot proven
- 2021-06-03VelphoroSucroferric OxyhydroxideNot proven
- 2020-10-01TybostCobicistatNot proven
- 2018-09-20VeltassaPatiromerNot proven
- 2015-03-19VelphoroSucroferric OxyhydroxideNot proven: 2 of 2 patient groups
- 2014-09-18TybostCobicistatNot proven
Data status: 2026-10-29